CA Patent

CA2076257A1 — 4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives

Assigned to Janssen Pharmaceutica NV · Expires 1993-03-14 · 33y expired

What this patent protects

ABSTRACT 4-[4-[4-(4-HYDROXYPHENYL)-1-PIPERAZINYL]PHENYL]-5-METHYL-3H-1,2,4-TRIAZOL-3-ONE 2-[2-(4-chlorophenyl)-2-(hydroxy or oxo)ethyl]-2,4-dihydro4-[4-[4-(4-hydroxy-phenyl)-l-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one having the formula (I), wherein X represents…

USPTO Abstract

ABSTRACT 4-[4-[4-(4-HYDROXYPHENYL)-1-PIPERAZINYL]PHENYL]-5-METHYL-3H-1,2,4-TRIAZOL-3-ONE 2-[2-(4-chlorophenyl)-2-(hydroxy or oxo)ethyl]-2,4-dihydro4-[4-[4-(4-hydroxy-phenyl)-l-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one having the formula (I), wherein X represents C=O or CHOH, for use as 5-lipoxygenase inhibitors. Pharmaceutical compositions, processes for preparing said compounds and compositions; and a method of treating leukotriene mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2076257A1
Jurisdiction
CA
Classification
—
Expires
1993-03-14
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.